Afficher la notice abrégée

Durable natural killer cell responses after heterologous two-dose Ebola vaccination

dc.rights.licenseopenen_US
dc.contributor.authorWAGSTAFFE, H. R.
dc.contributor.authorSUSANNINI, G.
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRICHERT, Laura
dc.contributor.authorLEVY, Y.
dc.contributor.authorBOCKSTAL, V.
dc.contributor.authorSTOOP, J. N.
dc.contributor.authorLUHN, K.
dc.contributor.authorDOUOGUIH, M.
dc.contributor.authorRILEY, E. M.
dc.contributor.authorLACABARATZ, C.
dc.contributor.authorGOODIER, M. R.
dc.date.accessioned2021-03-03T15:08:26Z
dc.date.available2021-03-03T15:08:26Z
dc.date.issued2021-01-29
dc.identifier.issn2059-0105 (Electronic) 2059-0105 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26406
dc.description.abstractEnNatural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo (EBOVAC2 consortium, EU Innovative Medicines Initiative), induces NK cell activation and anti-Ebola glycoprotein (GP) antibody-dependent NK cell activation post-dose 1, which is further elevated post-dose 2. Here, in a multicentre, phase 2 clinical trial (EBL2001), we demonstrate durable ex vivo NK cell activation 180 days after dose 2, with responses enriched in CD56(bright) NK cells. In vitro antibody-dependent responses to immobilised Ebola GP increased after dose 1, and remained elevated compared to pre-vaccination levels in serum collected 180 days later. Peak NK cell responses were observed post-dose 2 and NK cell IFN-γ responses remained significantly elevated at 180 days post-dose 2. Individual variation in NK cell responses were influenced by both anti-Ebola GP antibody concentrations and intrinsic interindividual differences in NK cell functional capacity. In summary, this study demonstrates durable NK cell responses after Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccination and could inform the immunological evaluation of future iterations of the vaccine regimen and vaccination schedules.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enDurable natural killer cell responses after heterologous two-dose Ebola vaccination
dc.title.alternativeNPJ Vaccinesen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41541-021-00280-0en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33514756en_US
bordeaux.journalNPJ vaccinesen_US
bordeaux.page19en_US
bordeaux.volume6en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamSISTM_BPH
bordeaux.teamHEALTHY_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03158135
hal.version1
hal.date.transferred2021-03-05T15:42:12Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=NPJ%20vaccines&rft.date=2021-01-29&rft.volume=6&rft.issue=1&rft.spage=19&rft.epage=19&rft.eissn=2059-0105%20(Electronic)%202059-0105%20(Linking)&rft.issn=2059-0105%20(Electronic)%202059-0105%20(Linking)&rft.au=WAGSTAFFE,%20H.%20R.&SUSANNINI,%20G.&THIEBAUT,%20Rodolphe&RICHERT,%20Laura&LEVY,%20Y.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_NPJV_2021_Wagstaffe.pdf
Taille:
1.620Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée